M. Numasaki
Impact in
- Immunology top 5%
- Psoriasis: Treatment and Pathogenesis
- Immunotherapy and Immune Responses
- Immune Cell Function and Interaction
- T-cell and B-cell Immunology
- Immune cells in cancer
- IL-33, ST2, and ILC Pathways
- Oncology top 10%
- Cancer Immunotherapy and Biomarkers
- Cytokine Signaling Pathways and Interactions
Papers in
- Oncology 3
- CAR-T cell therapy research 2
- Cytokine Signaling Pathways and Interactions 1
-
- Angiogenesis and VEGF in Cancer 1
- Co-authors
- Masatoshi Tagawa (2 shared papers)Shinya Okamoto (1 shared paper)K Kawamura (1 shared paper)Kiyoshi Takagi (1 shared paper)Hiroki Tsukamoto (1 shared paper)Yoshihisa Tomioka (1 shared paper)Michio Nagata (1 shared paper)Hideaki Shimada (1 shared paper)
- Journals
- British Journal of Cancer (1 paper)Cancer Gene Therapy (1 paper)Bioscience Biotechnology and Biochemistry (1 paper)Blood (1 paper)PubMed (1 paper)
- Partner nations
- JapanUnited States
In The Last Decade
M. Numasaki
4 papers receiving 686 citations
M. Numasaki's Hit Papers
Peers
Comparison fields: 5 of 66
- Immunology 518
- Oncology 342
- Dermatology 51
- Cancer Research 59
- Pathology and Forensic Medicine 60
Countries citing papers authored by M. Numasaki
This map shows the geographic impact of M. Numasaki's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by M. Numasaki with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites M. Numasaki more than expected).
Fields of papers citing papers by M. Numasaki
This network shows the impact of papers produced by M. Numasaki. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by M. Numasaki. The network helps show where M. Numasaki may publish in the future.
Co-authors
The 22 scholars most cited alongside M. Numasaki, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Interleukin-17 promotes angiogenesis and tumor growth Hit paper breakdown → | 2002 | 665 |
| 2 | 2011 | 14 | |
| 3 | 2016 | 13 | |
| 4 | 2024 | 2 | |
| 5 | [Change of cytokines and clinical efficacy of panipenem/betamipron in obstetric and gynecological infections. Yamagata Study Group of Panipenem/Betamipron in Obstetric and Gynecological Infections]. | 1998 | 1 |
About M. Numasaki
M. Numasaki is a scholar working on Oncology, Molecular Biology, Genetics, Immunology and Epidemiology, having authored 5 papers that have together received 695 indexed citations. Recurring topics across this work include CAR-T cell therapy research (2 papers), Immunotherapy and Immune Responses (2 papers), Virus-based gene therapy research (2 papers), Neonatal and Maternal Infections (1 paper), Cytokine Signaling Pathways and Interactions (1 paper), Systemic Lupus Erythematosus Research (1 paper), Angiogenesis and VEGF in Cancer (1 paper) and Adipokines, Inflammation, and Metabolic Diseases (1 paper). The work is most often cited by research in Immunology (518 citations), Oncology (342 citations), Dermatology (51 citations), Cancer Research (59 citations) and Pathology and Forensic Medicine (60 citations). M. Numasaki has collaborated with scholars based in Japan and United States. Frequent co-authors include Masatoshi Tagawa, Shinya Okamoto, K Kawamura, Kiyoshi Takagi, Hiroki Tsukamoto, Yoshihisa Tomioka, Michio Nagata, Hideaki Shimada, Takuji Suzuki and Yasuhiko Nishioka. Their work appears in journals such as British Journal of Cancer, Cancer Gene Therapy, Bioscience Biotechnology and Biochemistry, Blood and PubMed.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.